T- or NK-cell recruiting anti-EGFRvIII TandAbs are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors
Ellwanger et al.
AACR 2016
Ellwanger et al.
AACR 2016
Ellwanger et al.
AACR 2016
Rothe et al.
Blood. 2015. Jun 25; 125(26): 4024-31. doi: 10.1182/ blood-2014-12-614636. Epub 2015 Apr 17./.
Hutchings M.
Blood. 2015 Jun 25; 125(26): 3967-8.doi: 10.1182/ blood-2015-05-641712./.
Ellwanger et al.
CIMT 2015
Reusch et al.
MAbs. 2015 May 4; 7(3):584-604. doi: 10.1080/19420862.2015.1029216. [PubMed - in process].
Eissenberg et al.
ASCO 2015
Reusch et al.
ASCO 2015
Reusch et al.
ASCO 2015
Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32